Blueprint Medicines Corp (BPMC)
87.22
+0.40
(+0.46%)
USD |
NASDAQ |
Dec 31, 16:00
87.17
-0.05
(-0.06%)
Pre-Market: 20:00
Blueprint Medicines SG&A Expense (Quarterly): 89.93M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 371.80M |
| PTC Therapeutics Inc | 73.46M |
| Biomarin Pharmaceutical Inc | 253.50M |
| Regeneron Pharmaceuticals Inc | 714.40M |
| SpringWorks Therapeutics Inc | 61.60M |